<DOC>
	<DOCNO>NCT01779375</DOCNO>
	<brief_summary>The RISE Pediatric Medication Study 2-arm , 4-center , clinical trial child prediabetes early type 2 diabetes address hypothesis aggressive glucose lower lead recovery beta-cell function sustain withdrawal treatment . Pediatric participant ( age 10-19 ) randomize one follow treatment regimen : ( 1 ) metformin alone ( 2 ) early intensive treatment basal insulin glargine follow metformin . The primary clinical question RISE address : Are improvement ß-cell function follow 12 month active treatment maintain 3 month follow withdrawal therapy ? Secondary outcome assess durability glucose tolerance follow withdrawal therapy , whether biomarkers obtain fast state predict parameter ß-cell function , insulin sensitivity glucose tolerance response intervention .</brief_summary>
	<brief_title>RISE Pediatric Medication Study</brief_title>
	<detailed_description />
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>1 . Fasting plasma glucose ≥90 mg/dl plus 2hour glucose ≥140 mg/dl 75 gm OGTT plus laboratorybased HbA1c ≤8.0 % treatment naïve . There upper limit 2hour glucose OGTT . In take metformin laboratorybased HbA1c must ≤7.5 % metformin &lt; 3 month ≤7.0 % metformin 36 month . 2 . Age 1019 year 3 . Pubertal development Tanner stage &gt; 1 define breast stage &gt; 1 girl , testis &gt; 3 cc 's boy . 4 . Body mass index ( BMI ) ≥85th percentile ≤50 kg/m2 5 . Selfreported diabetes &lt; 6 month duration 6 . Treatment metformin &lt; 6 month precede screen 1 . Underlying disease likely limit life span and/or increase risk intervention underlie condition likely limit ability participate outcome assessment 2 . An underlying disease affect glucose metabolism type 2 diabetes mellitus 3 . Taking medication affect glucose metabolism , underlie condition likely require medication 4 . Treatment insulin &gt; 1 week precede screen 5 . Active infection 6 . Renal disease ( serum creatinine &gt; 1.2 mg/dl ) serum potassium abnormality ( &lt; 3.4 &gt; 5.5 mmol/l ) 7 . Anemia ( hemoglobin &lt; 11 g/dl girl , &lt; 12 g/dl boy ) know coagulopathy 8 . Cardiovascular disease , include uncontrolled hypertension define average systolic diastolic blood pressure &gt; 99 percentile age &gt; 135/90 , despite adequately prescribe antihypertensive medication . Participants must able safely tolerate administration intravenous fluid require clamp study . 9 . History condition may precipitate exacerbated study drug : 1 . Serum alanine transaminase ( ALT ) 3 time upper limit normal 2 . Excessive alcohol intake 3 . Suboptimally treat thyroid disease 10 . Conditions behavior likely affect conduct RISE Study 1 . Participant and/or parent unable unwilling give inform consent 2 . Participant and/or parent unable adequately communicate clinic staff 3 . Another household member participant staff member RISE 4 . Current , recent anticipated participation another intervention research project would interfere interventions/outcomes RISE 5 . Weight loss ≥5 % body weight past 3 month reason postpartum weight loss . Participants take weight loss drug use preparation take intended weight loss exclude . 6 . Likely move away participate clinic next 2 year 7 . Current ( anticipate ) pregnancy lactation . 8 . A pregnancy complete less 6 month prior screen . 9 . Breast feeding within 6 month prior screen . 10 . Women childbearing potential unwilling use adequate contraception 11 . Major psychiatric disorder , opinion clinic staff , would impede conduct RISE 11 . Additional condition may serve criterion exclusion discretion local site .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Children</keyword>
	<keyword>Pediatric</keyword>
</DOC>